Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
CA 2714357 C · Owner: Berkovic, Samuel Frank · Inventors: Mulley, John Charles; Wallace, Robyn Heather; Berkovic, Samuel Frank
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The mutations D188V, V1353L, I1656M in the neuronal gene sodium-channel alphal-subunit SCN1A, are disclosed. The methods of using their associated polypeptides for treating sodium channel dysfunction disorders including generalised epilepsy are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 20, 2001 and granted November 12, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 20, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 20, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.